This HTML5 document contains 48 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n11http://linked.opendata.cz/resource/drugbank/mixture/
n9http://linked.opendata.cz/resource/drugbank/drug/DB08830/identifier/chebi/
n6http://bio2rdf.org/drugbank:
n13http://linked.opendata.cz/resource/drugbank/drug/DB08830/identifier/wikipedia/
admshttp://www.w3.org/ns/adms#
n12http://linked.opendata.cz/resource/drugbank/drug/DB08830/identifier/kegg-compound/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n10http://linked.opendata.cz/resource/drugbank/drug/DB08830/identifier/drugbank/

Statements

Subject Item
n2:DB08830
rdf:type
n3:Drug
n3:description
Dehydroascorbic acid is made from the oxidation of ascorbic acid. This reaction is reversible, but dehydroascorbic acid can instead undergo irreversible hydrolysis to 2,3-diketogulonic acid. Dehydroascorbic acid as well as ascorbic acid are both termed Vitamin C, but the latter is the main form found in humans. In the body, both dehydroascorbic acid and ascorbic acid have similar biological activity as antivirals but dehydroascorbic acid also has neuroprotective effects. Currently dehydroascorbic acid is an experimental drug with no known approved indications.
n3:generalReferences
# AHFS Drug Information. # Agus DB, Gambhir SS, Pardridge WM, Spielholz C, Baselga J, Vera JC, Golde DW: Vitamin C crosses the blood-brain barrier in the oxidized form through the glucose transporters. J Clin Invest. 1997 Dec 1;100(11):2842-8. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/9389750 # Huang J, Agus DB, Winfree CJ, Kiss S, Mack WJ, McTaggart RA, Choudhri TF, Kim LJ, Mocco J, Pinsky DJ, Fox WD, Israel RJ, Boyd TA, Golde DW, Connolly ES Jr: Dehydroascorbic acid, a blood-brain barrier transportable form of vitamin C, mediates potent cerebroprotection in experimental stroke. Proc Natl Acad Sci U S A. 2001 Sep 25;98(20):11720-4. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11573006 # Furuya A, Uozaki M, Yamasaki H, Arakawa T, Arita M, Koyama AH: Antiviral effects of ascorbic and dehydroascorbic acids in vitro. Int J Mol Med. 2008 Oct;22(4):541-5. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/18813862
n3:group
experimental
n3:indication
There is no approved indication for dehydroascorbic acid, but it has potential therapeutic use in patients with certain viruses and ischemic stroke.
owl:sameAs
n6:DB08830
dcterms:title
Dehydroascorbic Acid
adms:identifier
n9:27956 n10:DB08830 n12:C05422 n13:Dehydroascorbic_acid
n3:mechanismOfAction
Even though dehydroascorbic acid and ascorbic acid have similar effects, their mechanism of action seems to be different. The exact mechanism of action is still being investigated, but some have been elucidated. Concerning dehydroascorbic acid's antiviral effect against herpes simplex virus type 1, it is suggested that dehydroascorbic acid acts after replication of viral DNA and prevents the assembly of progeny virus particles.
n3:synonym
Dehydroascorbate L-Dehydroascorbate L-dehydroascorbic acid
n3:mixture
n11:271B57A8-363D-11E5-9242-09173F13E4C5
n3:IUPAC-Name
n4:271B57AD-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B57B3-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B57B2-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B57AF-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B57B0-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B57B1-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B57AB-363D-11E5-9242-09173F13E4C5 n4:271B57C3-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B57A9-363D-11E5-9242-09173F13E4C5 n4:271B57AC-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B57AA-363D-11E5-9242-09173F13E4C5
n3:pKa
n4:271B57C5-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n4:271B57B9-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B57BA-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B57B4-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B57B5-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B57B7-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B57B6-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B57B8-363D-11E5-9242-09173F13E4C5
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
490-83-5
n3:category
n3:Bioavailability
n4:271B57BF-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B57C1-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B57C2-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B57C4-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B57BE-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B57BD-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B57C0-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B57AE-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B57BB-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B57BC-363D-11E5-9242-09173F13E4C5